[1] McKhann GM, Knopman DS, Chertkow H, et al.The diagnosis of dementia due to Alzheimer′s disease: recommendations from the National Institute on Aging-Alzheimer′s Association workgroups on diagnostic guidelines for Alzheimer′s disease[J].Alzheimers Dement, 2011, 7(3): 263-269.
[2] Colletier JP, Laganowsky A, Landau M, et al.Molecular basis for amyloid-beta polymorphism[J].Proc Natl Acad Sci USA, 2011, 108(41): 16938-16943.
[3] Jeong JS, Ansaloni A, Mezzenga R, et al.Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation[J].J Mol Biol, 2013, 425(10): 1765-1781.
[4] Kawahara M.Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis[J].Curr Pharm Des, 2010, 16(25): 2779-2789.
[5] Hatashita S, Yamasaki H.Clinically different stages of Alzheimer′s disease associated by amyloid deposition with [11C]-PIB PET imaging[J].J Alzheimers Dis, 2010, 21(3): 995-1003.
[6] Vandenberghe R, Van Laere K, Ivanoiu A, et al.18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial[J].Ann Neurol, 2010, 68(3): 319-329.
[7] Hsiao IT, Huang CC, Hsieh CJ, et al.Correlation of early-phase 18F-florbetapir(AV-45/Amyvid) PET images to FDG images: preliminary studies[J].Eur J Nucl Med Mol Imaging, 2012, 39(4): 613-620.
[8] Becker GA, Ichise M, Barthel H, et al.PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains[J].J Nucl Med, 2013, 54(5): 723-731.
[9] Tauber C, Beaufils E, Hommet C, et al.Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients[J].J Alzheimers Dis, 2013, 36(2): 311-320.
[10] Okamura N, Furumoto S, Harada R, et al.Novel 18F-Labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease[J].J Nucl Med, 2013, 54(8): 1420-1427.
[11] Mathis CA, Bacskai BJ, Kajdasz ST, et al.A lipophilic thioflavin-T derivative for positron emission tomography(PET) imaging of amyloid in brain[J].Bioorg Med Chem Lett, 2002, 12(3): 295-298.
[12] Kemppainen NM, Scheinin NM, Koivunen J, et al.Five-year follow-up of 11C-PIB uptake in Alzheimer′s disease and MCI[J].Eur J Nucl Med Mol Imaging, 2014, 41(2): 283-289.
[13] Clark CM, Schneider JA, Bedell BJ, et al.Use of florbetapir-PET for imaging beta-amyloid pathology[J].JAMA, 2011, 305(3): 275-283.
[14] Rinne JO, Wong DF, Wolk DA, et al. [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies[J].Acta Neuropathol, 2012, 124(6): 833-845.
[15] Hatashita S, Yamasaki H, Suzuki Y, et al. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer′s disease[J].Eur J Nucl Med Mol Imaging, 2014, 41(2): 290-300.
[16] Barthel H, Gertz HJ, Dresel S, et al.Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer′s disease and healthy controls: a multicentre phase 2 diagnostic study[J].Lancet Neurol, 2011, 10(5): 424-435.
[17] Rominger A, Brendel M, Burgold S, et al.Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET[J].J Nucl Med, 2013, 54(7): 1127-1134.
[18] Thompson PW, Ye L, Morgenstern JL, et al.Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer′s disease pathologies[J].J Neurochem, 2009, 109(2): 623-630.
[19] Ercoli LM, Siddarth P, Kepe V, et al.Differential FDDNP PET patternsin nondemented middle-aged and older adults[J].Am J Geriatr Psychiatry, 2009, 17(5): 397-406.
[20] Tolboom N, Yaqub M, van der Flier WM, et al.Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET[J].J Nucl Med, 2009, 50(2): 191-197.
[21] Tolboom N, van der Flier WM, Boverhoff J, et al.Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C] PIB and[18F] FDDNP PET images[J].J Neurol Neurosurg Psychiatry, 2010, 81(8): 882-884.
[22] Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al.Longitudinal imaging of Alzheimer pathology using [11C] PIB, [18F] FDDNP and [18F] FDG PET[J].Eur J Nucl Med Mol Imaging, 2012, 39(6): 990-1000.
[23] Fodero-Tavoletti MT, Okamura N, Furumoto S, et al.18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease[J].Brain, 2011, 134(4): 1089-1000.
[24] Chien DT, Bahri S, Szardenings AK, et al.Early clinical PET imaging results with the novel PHF-tau radioligand[F-18]-T807[J].J Alzheimers Dis, 2013, 34(2): 457-468.
[25] Van Camp N, Boisgard R, Kuhnast B, et al.In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model[J].Eur J Nucl Med Mol Imaging, 2010, 37(5): 962-972.
[26] Wang M, Gao M, Miller KD, et al.Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic(PET)imaging of the translocator protein(TSPO)[J].Steroids, 2011, 76(12): 1331-1340.
[27] Damont A, Boisgard R, Kuhnast B, et al.Synthesis of 6- [18F] fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET[J].Bioorg Med Chem Lett, 2011, 21(16): 4819-4822.
[28] Wilms H, Claasen J, Röhl C, et al.Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro[J].Neurobiol Dis, 2003, 14(3): 417-424.
[29] Pascual B, Prieto E, Arbizu J, et al.Decreased carbon-11-flumazenil binding in early Alzheimer's disease[J].Brain, 2012, 135(Pt 9): 2817-2825.
[30] Wong DF, Waterhouse R, Kuwabara H, et al.18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry[J].J Nucl Med, 2013, 54(3): 388-396.
[31] Constantinescu CC, Garcia A, Mirbolooki MR, et al.Evaluation of [18F] Nifene biodistribution and dosimetry based on whole-body PET imaging of mice[J].Nucl Med Biol, 2013, 40(2): 289-294.
[32] Kuwabara H, Wong DF, Gao Y, et al.PET Imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics[J].J Nucl Med, 2012, 53(1): 121-129.
[33] Bucerius J, Manka C, Schmaljohann J, et al.Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo[J].JACC Cardiovasc Imaging, 2012, 5(5): 528-536.